Introduction
============

Urothelial carcinomas (UCs) originate from the urothelial cells, the epithelial lining of the entire urinary tract from the upper urinary tract (UT) to urinary bladder (UB). The former consists of the renal pelvis and ureter. UC is the predominant histopathological type of UT malignancy, constituting \>90% cases of UT cancer in developed countries.[@B1] UC of the UB (UCUB) is a relatively common cancer in developed countries. For instance, it is the seventh most prevailing malignancy in the United States.[@B2] In contrast to the relatively high prevalence of UCUB, UC of the UT (UCUT) is uncommon and forms only five to ten percent of all victims of UC.[@B3] Nevertheless, the prevalence of UCUT is exceptionally high in Taiwan, particularly in southern Taiwan and blackfoot-disease-endemic areas.[@B4],[@B5] Etiologically, both UCUB and UCUT are caused by similar carcinogenic factors (e.g*.*, tobacco smoking and occupational hazard of aromatic amines).[@B6]-[@B8] However, certain diseases predispose patients to UCUT rather than to UCUB, such as Chinese herb nephropathy,[@B9] Balkan nephropathy,[@B9] and analgesic nephropathy.[@B10] Nonetheless, the gene expression profiling of both UCUTs and UCUBs revealed similar results.[@B11] In addition, the survival rates of patients in both groups were similar, considering the tumor stage and grade.[@B12] These findings indicate that both UCUT and UCUB share a molecular pathway.

The immune system is a double-edged sword to cancer. It can recognize and kill nascent tumor cells through a complex mechanism called cancer immunosurveillance.[@B13] By contrast, chronic inflammation induced by variable etiologies contributes to tumorigenesis in certain cancers.[@B14] The complement system is an essential pathway in immunology and is implicated in cancer development, progression and susceptibility;[@B15]-[@B17] the components of the complement system exhibit peptidase activity.[@B18] Recently, various peptidases have been investigated in different cancers, thus revealing their prognostic value.[@B19],[@B20] However, neither genes associated with peptidase activity nor the complement system are comprehensively and systemically evaluated in UC. Therefore, we conducted data mining on a documented transcript expression profile (GSE31684) obtained from the Gene Expression Omnibus (GEO, National Center for Biotechnology Information, Bethesda, MD, USA) repository and focused on peptidase activity (GO:0008233). We found that the transcription level of the complement component 1, s subcomponent (*C1S)* was most momentously upregulated, which was positively associated with both tumor invasiveness and metastases. This finding indicates that the *C1S* gene may take an important part in oncogenesis and tumor progression of UC. In the following research, we found C1S transcriptional levels were significantly higher in more advanced tumors. In addition, we firstly demonstrated that C1s protein overexpression was not only significantly associated with adverse clinicopathological features, but also a novel prognostic factor indicating poor outcome in both UCUTs and UCUBs.

Materials and Methods
=====================

Data Mining of GSE31684 to Identify the Most Significantly Altered Genes
------------------------------------------------------------------------

The transcriptome data set GSE31684 used for data mining was obtained from the GEO repository of NCBI. A GeneChip^®^ Human Genome U133 Plus 2.0 array (Affymetrix, Santa Clara, CA, USA) was used for analyzing the data set (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31684>) involving radical cystectomy specimens from 93 patients with UCUB. We used Nexus Expression 3 statistical software (BioDiscovery, El Segundo, CA, USA) to analyze all probe sets without filtering or preselection. Furthermore, under supervision, we analyzed the statistical significance of each differently expressed transcript by comparing the primary tumor status (high stage to low stage) and the presence or absence of metastatic events. We performed functional profiling by using transcriptomes of high-stage UCUBs (primary tumor \[pT\]2-pT4) with metastatic disease and of low-stage UCUBs (pTa and pT1) without metastatic tumor, aiming attention at those associated with peptidase activity (GO:0008233).

Patient and Tumor Specimen Selection
------------------------------------

This study was approved by the Institutional Review Board (IRB) of Chi Mei Medical Center, Tainan, Taiwan (IRB10302015) and E-Da Hospital, Kaohsiung, Taiwan (EMRP-104-123). We enrolled 635 consecutive surgically treated patients diagnosed with UC with curative intent between 1996 and 2004 from the archives of the Department of Pathology. Among the patients, 295 and 340 had UCUB and UCUT, respectively. Other histopathological entities as well as UC variants were excluded from this study. Patients with synchronous UCUT and UCUB were also excluded. Detailed treatment protocol was the same as our previous work.[@B21]

Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) for Assessing the Transcription Levels of *C1S* in UCUBs and UCUTs
-------------------------------------------------------------------------------------------------------------------------------------

For quantifying the transcription level of *C1S*, we extracted total RNAs from a recently diagnosed, separate cohort of 20 patients with UCUTs and 20 with UCUBs; we quantified the extracted RNAs and subjected them to a real-time reverse-transcription polymerase chain reaction (qPCR). Both groups comprised 10 low-stage (pTa-pT1) and 10 high-stage (pT2-pT4) tumors. By using predesigned TaqMan assay reagents (Applied Biosystems, Waltham, MA, USA), we assessed the mRNA abundance of *C1S* (Hs01043795_m1) through the ABI StepOnePlus™ system (Applied Biosystems). We calculated the fold change of *C1S* gene expression of UC tumors relative to the normal counterparts as previously described.[@B21]

Immunohistochemical Study and Evaluation of C1s Expression
----------------------------------------------------------

Tumor slides were prepared as previously described.[@B21] After that, the slides were subsequently proceeded to incubation with primary antibody against C1s (Rabbit monoclonal, clone: EPR9066 (B), Cat No. ab134943, Abcam, Cambridge, United Kingdom) for 1 hour. We scored C1s protein expression levels by combining the intensity and percentage of immunostaining in the cytoplasm of UC cells to create an H score. The equation for evaluating the H score is as follows: H score = Σ*P~i~*(*i*+ 1), where *Pi* represents the percentage of stained tumor cells for each percentage varying from 0% to 100%, and *i* means the intensity of immunoreactivity (0-3+). This formula yields a score ranging from 100 to 400, where 100 signifies that 100% of the cancer cells are unreactive and 400 signifies that 100% of the cancer cells are strongly immunoreactive (3+).

Statistical Analyses
--------------------

We used SPSS V.14.0 software (SPSS Inc., Chicago, IL, USA) for statistical analysis. The C1s immunoreactivity median H score was applied as the cutoff point to bisect the two groups, UCUTs and UCUBs, into two subgroups, high- and low-C1s expression, respectively. We applied Pearson\'s χ^2^ test to compare the association between C1s expression and miscellaneous important clinicopathological parameters. The end-points analyzed included disease-specific (DSS) and metastasis-free survival (MeFS) as described in our previous work.[@B21] Kaplan-Meier plots with log-rank test were used for univariate analyses, in which parameters demonstrating *P*\< .1 were included in multivariate Cox proportional hazards regression. For the above-mentioned tests, two-tailed testing was conducted, and *P*\< .05 was considered to be significant.

Results
=======

*C1S* Gene was the Most Significantly Upregulated Gene Associated with Tumor Progression in UCUB Transcriptomes
---------------------------------------------------------------------------------------------------------------

The analyzed transcriptome data set involved specimens from 93 patients with UCUBs; among these patients, 78 exhibited deeply invasive tumors (pT2-pT4) and 15 exhibited non-invasive or superficially invasive (pTa-pT1), of which 28 demonstrated metastases and 49 did not. Through transcriptome profiling, we identified 12 probes covering 12 transcripts associated with peptidase activity (GO:0008233). **Fig. [1](#F1){ref-type="fig"}** shows that tumors with downregulated *USP31*, *AGBL2*, *SPPL2B*, and *MMP28* as well as upregulated *C1S*, *FAP*, *PCSKS*, *CPXM1*, *PCSK1*, *CPE*, *ADAMTS3*, and *PRSS35* tended to have a more advanced pT status and more frequent metastatic events compared with other tumors. As shown in **Table [1](#T1){ref-type="table"},** after the statistical analysis, the *C1S* transcript was the most significantly upregulated gene, with 1.4602- and 0.9181-fold log2 ratios compared with those of genes in both deeply invasive (pT2-pT4) and non-invasive to superficially invasive (pTa-pT1) tumors with or without metastases, respectively (both *P*\< .005). No study has examined *C1S* in UC; therefore, we comprehensively investigated both*C1S* transcriptional and protein expression levels and their clinical significance in UC.

*C1S* Transcripts were More Abundant in More Advanced Tumors of Both UCUT and UCUB Groups
-----------------------------------------------------------------------------------------

Real-time RT-PCR revealed that the *C1S* transcripts were significantly more abundant in tumors of a higher pT status (pT2-pT4) than in those of a lower pT status (pTa-pT1) in the 20 patients with UCUTs and 20 with UCUBs (*P*= .001 and .002 for UCUT and UCUB, respectively; **Fig. [2](#F2){ref-type="fig"}**), suggesting that *C1S* takes an influential part in UC advancement.

Clinical and pathological Characteristics of UCUTs and UCUBs
------------------------------------------------------------

**Table [2](#T2){ref-type="table"}** presents a summary of the clinical and pathological features of both UCUT and UCUB groups. No sex predominance was observed in the UCUT group (M:F = 158:182, 46.5%:53.5%); however, male predominance was observed in the UCUB group (n = 216, 73.2%). Moreover, 159 (46.8%) patients with UCUT and 123 (41.7%) with UCUB had high-stage (pT2-pT4) tumors, whereas 181 (53.2%) patients with UCUTs and 172 (58.3%) with UCUBs had low-stage (pTa-pT1) tumors; 28 (8.2%) patients with UCUTs and 29 (9.8%) with UCUBs had nodal metastases at diagnosis. In both groups, most tumors were of a high histopathological grade (83.5% for UCUT and 81.0% for UCUB, respectively). Vascular invasion and perineural invasion were observed in 106 (31.1%) and 19 (5.6%) patients with UCUT as well as in 49 (16.6%) and 20 (6.8%) patients with UCUB, respectively. Furthermore, 167 (49.1%) patients with UCUT and 156 (52.9%) with UCUB revealed high mitotic activity (10 or more mitoses per 10 high-power fields). In the UCUT group, synchronous multifocal tumors occurred in 62 (18.2%) patients; of these, both renal pelvis and ureter were involved in 49 (14.4%) patients.

C1s Immunostaining and Clinicopathological Correlations in UCUTs and UCUBs
--------------------------------------------------------------------------

According to the C1s expression levels, both study groups were divided into two subgroups, namely high and low C1s expression, and their association with diverse clinicopathological parameters was analyzed through a chi-squared test (**Table [2](#T2){ref-type="table"})**. A high C1s expression level in both UCUTs and UCUBs was significantly associated with a stepwise advancement of primary tumor status from pTa and pT1 to pT2-pT4 (both *P*\< .001, **Fig. [3](#F3){ref-type="fig"}**), metastatic tumors to lymph nodes (*P*= .006 for UCUT and *P*\< .001 for UCUB), a high histopathological grade (both *P*\< .001), vascular invasion (both *P*\< .001), perineural invasion (*P*= .034 for UCUT; *P*= .021 for UCUB), and a high mitotic activity (*P*= .039 for UCUT; *P*= .003 for UCUB).

Survival Analyses for the UCUT Group
------------------------------------

**Table [3](#T3){ref-type="table"}** shows the results of the survival analyses for the UCUT group. In the univariate analysis, multifocality, a stepwise advancement of the pT status, nodal metastasis, a high histopathological grade, vascular and perineural invasion were significantly associated with both shorter DSS and MeFS for UCUT tumors (all *P*\< .05). The tumor location was associated with deteriorated DSS rates, but not MeFS rates, in patients with UCUT (*P*= .0079). In the multivariate analysis, multifocal tumors, nodal metastasis, a high histological grade, and perineural invasion independently predicted both adverse DSS and MeFS rates in patients with UCUT (all *P* \< .05). An advanced pT status was independent prognosticator for the DSS only (*P*= .015); and vascular invasion was independent one for MeFs only (*P*= .003).

Survival Analyses for the UCUB Group
------------------------------------

**Table [4](#T4){ref-type="table"}** presents the results of the survival analyses for UCUBs. In the univariate analysis, a stepwise advancement of the primary tumor status (pT), nodal metastasis, a increment of histopathological grade, vascular/perineural infiltration, and a high mitotic activity were positively associated with both poorer disease-specific and metastasis-free survival rates (all *P* \< .05). In the multivariate analysis, a stepwise advancement of the pT status and high mitotic activity were significantly associated with poorer disease-specific and metastasis-free survival rates (all *P* \< .05). By contrast, perineural invasion independently predicted only DSS rates, but not MeFS rates, in patients with UCUB (*P*= .018).

Prognostic Significance of C1s Immunoreactivity in UCUTs and UCUBs
------------------------------------------------------------------

As shown in **Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}** and **Fig. [4](#F4){ref-type="fig"}**, a high C1s expression level confers significant poor DSS and MeFS for both groups in the univariate analysis (all *P*\< .0001). Moreover, C1s overexpression independently predicted poor DSS and MeFS rates for all UC patients in the multivariate analysis (all *P*\< .01).

Discussion
==========

UC is cancer type of cancer exhibiting high recurrence rates.[@B22] The survival rate is also poor for patients with advanced disease.[@B23],[@B24] Hence, it is imperative for researchers to investigate new treatment targets in high-risk patients. Chronic inflammation participates in the tumorigenesis of certain cancers, including UC,[@B25],[@B26] by inducing cytokines, growth factors, reactive oxygen species (ROS), and others.[@B14] ROS cause oxidative stress and an oxidation-reduction imbalance. The downregulation of certain proteins causing oxidative stress is also associated with poor prognosis in both UCUT and UCUB.[@B27] By subjecting a published transcriptomic database (GSE31684) of UCUBs to data mining and focusing on peptidase activity (GO:0008233), we identified *C1S* as the most significantly upregulated gene related to advanced disease. In the ex vivo study, we also demonstrated that the upregulation and overexpression of *C1S* considering both mRNA and protein levels were associated with adverse clinicopathological parameters and also predicted poor prognosis in both UCUT and UCUB.

The complement system is a member of the innate immunity and plays a critical role in host defense. It contains a group of circulating glycoproteins that promote inflammation. The complement system comprises three major pathways: the classical, alternative, and mannan-binding lectin pathways.[@B28] The classical pathway is triggered by the binding of the Fc region of antigen-bound antibody molecules to C1 components. The initial enzyme, C1, is a complex protein comprising one C1q molecule, two C1r molecules, and two C1s molecules. The molecular weight of C1s is 85 kDa, and its concentration in human plasma is approximately 50 μg/mL.[@B18] C1s contains serine protease activity, which splits C4 and then C2 to generate C4b2a, also known as C3 convertase. As the cascade proceeds, a membrane attack complex is formed.

Although the complement system has been studied in certain malignant tumors and carcinogenesis,[@B15]-[@B17] C1s is seldom investigated in cancers. Sakai et al*.* reported that when hamster complement C1s cDNA was transfected into BALB/c mouse fibroblast A31 cells, the transfectants formed tumors in BALB/c-nu/nu mice.[@B29] In a subsequent study, the same authors transfected mutant C1s cDNA into A31 cells. However, the transfectants, which produced *C1S* without enzyme activity, did not form tumors in nude mice.[@B30] In a recent study, the expression of *C1S* and other genes of the complement system was suppressed in paclitaxel-treated hypopharynx cancer cells.[@B31] Furthermore, conformationally altered hyaluronan (HA) inhibited C1s activation and other components of the complement system in DU145 prostate cancer cells.[@B32] The underexpression of HA synthase 3 (HAS3), one of the three HA synthases, is associated with adverse outcome and advanced disease in both UCUTs and UCUBs.[@B33] These observations imply that C1s plays an essential role in carcinogenesis, and its expression in chemosensitive hypopharyngeal cancer cells can be suppressed through chemotherapy. The association between C1s and HAS3 is also intriguing. The underexpression of HAS3 resulting in a lower production of HA, a potential C1s suppressor, in addition to the overexpression of C1s may exert a synergistic effect on the carcinogenesis and tumor progression of both groups of UCs.

Conclusions
===========

In summary, the present study demonstrated that C1s overexpression was not only indicators of unfavorable clinicopathological parameters but also independent prognostic factors that predict poor DSS and MeFS rates in patients with UCUTs or UCUBs. We have recently presented promising targets for new strategies in UC therapy.[@B34]-[@B37] Therefore, additional studies must be conducted to elucidate the details of the biological significance of *C1S* and its encoded protein in UC oncogenesis for exploring the possible C1s-targeted therapy for both groups of UCs.
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![**Analysis of gene expression in urothelial carcinoma of the urinary bladder by using a published transcriptome data set (GSE31684).**Conducting a clustering analysis of genes by focusing on peptidase activity (GO:0008233) revealed that *C1S* was one of the most significantly upregulated genes associated with a more advanced pT status and metastatic disease. Tissue specimens from cancers with distinct pT statuses are illustrated at the top of the heat map, and the expression levels of upregulated and downregulated genes are represented as a continuum of brightness of red or green, respectively. Specimens with unaltered mRNA expression are in black.](jcav07p1396g001){#F1}

![**Quantitative real-time reverse-transcription polymerase chain reaction analysis.**This analysis revealed a significantly higher *C1S* transcription level in both urothelial carcinomas of the upper urinary tract (left panel) and urinary bladder (right panel), with a more advanced primary tumor aggressiveness, compared with non-invasive and superficially invasive tumors (pTa-pT1) and deeply invasive ones (pT2-pT4), respectively (all *P*\< .005).](jcav07p1396g002){#F2}

![**C1s immunostain** on representative sections revealed a stepwise increment in C1s immunoreactivity from the nontumoral urothelial epithelium **(inlet)** and non-invasive papillary urothelial carcinomas **(A)**to non-muscle invasive (pT1) **(B)**, and muscle invasive (pT2-pT4) urothelial carcinomas **(C)**.](jcav07p1396g003){#F3}

![**Kaplan-Meier plots** revealed the significant prognostic value of C1s expression for disease-specific survival (DSS) and metastasis-free survival (MeFS) rates in the UCUT (**A** and **B** for DSS and MeFS, respectively) and UCUB (**C**and**D** for DSS and MeFS, respectively**)** groups (all *P*\< .0001).](jcav07p1396g004){#F4}

###### 

Summary of differentially expressed genes associated with peptidase activity (GO:0008233) and showed positive associations to cancer invasiveness and metastasis in the transcriptome of urothelial carcinoma of urinary bladder (GSE31684).

  6.5             Comparing T2-4 to Ta-T1   Comparing Meta. to Non-Meta.^\#^   Gene Symbol   Gene Title   Molecular Function                                                               
  --------------- ------------------------- ---------------------------------- ------------- ------------ -------------------- ----------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1555229_a\_at   1.4602                    0.0001                             0.9181        0.0013       *C1S*                complement component 1; s subcomponent                      calcium ion binding, complement component C1s activity, hydrolase activity, metal ion binding, peptidase activity, rhodopsin-like receptor activity, serine-type endopeptidase activity, serine-type endopeptidase inhibitor activity, serine-type peptidase activity
  201117_s\_at    1.081                     0.0048                             0.8652        0.0037       *CPE*                carboxypeptidase E                                          carboxypeptidase A activity, carboxypeptidase E activity, carboxypeptidase activity, hydrolase activity, metal ion binding, metallopeptidase activity, peptidase activity, zinc ion binding
  205825_at       0.3938                    0.0087                             0.3003        0.0088       *PCSK1*              proprotein convertase subtilisin/kexin type 1               calcium ion binding, hydrolase activity, peptidase activity, proprotein convertase 1 activity, serine-type endopeptidase activity, subtilase activity
  209955_s\_at    1.5836                    \<0.0001                           0.5783        0.0051       *FAP*                fibroblast activation protein; alpha                        dipeptidyl-peptidase IV activity, hydrolase activity, metalloendopeptidase activity, peptidase activity, prolyl oligopeptidase activity, protein dimerization activity, protein homodimerization activity, serine-type endopeptidase activity, serine-type peptidase activity
  213652_at       0.5635                    \<0.0001                           0.3841        0.0002       *PCSK5*              proprotein convertase subtilisin/kexin type 5               hydrolase activity, peptidase activity, serine-type endopeptidase activity, subtilase activity
  214913_at       0.2909                    0.0009                             0.2036        0.0025       *ADAMTS3*            ADAM metallopeptidase with thrombospondin type 1 motif; 3   heparin binding, hydrolase activity, metal ion binding, metalloendopeptidase activity, metallopeptidase activity, peptidase activity, zinc ion binding
  227860_at       0.6945                    \<0.0001                           0.4549        0.0001       *CPXM1*              carboxypeptidase X (M14 family); member 1                   carboxypeptidase A activity, carboxypeptidase E activity, carboxypeptidase activity, hydrolase activity, metal ion binding, metallopeptidase activity, peptidase activity, zinc ion binding
  235874_at       0.3376                    0.0001                             0.2276        0.0007       *PRSS35*             protease; serine; 35                                        peptidase activity, serine-type endopeptidase activity
  1558117_s\_at   -0.5337                   0.0039                             -0.4279       0.0026       *USP31*              ubiquitin specific peptidase 31                             cysteine-type peptidase activity, hydrolase activity, peptidase activity, ubiquitin thiolesterase activity
  210693_at       -0.376                    \<0.0001                           -0.1507       0.001        *SPPL2B*             signal peptide peptidase-like 2B                            aspartic-type endopeptidase activity, hydrolase activity, peptidase activity
  220390_at       -0.1759                   0.0032                             -0.1536       0.0007       *AGBL2*              ATP/GTP binding protein-like 2                              carboxypeptidase A activity, carboxypeptidase activity, hydrolase activity, metal ion binding, metallopeptidase activity, peptidase activity, zinc ion binding
  239272_at       -1.4769                   \<0.0001                           -0.7875       0.0022       *MMP28*              matrix metallopeptidase 28                                  calcium ion binding, hydrolase activity, metal ion binding, metalloendopeptidase activity, metallopeptidase activity, peptidase activity, zinc ion binding

\#, Meta., distal metastasis developed during follow-up; Non-Meta.: no metastatic event developed.

###### 

Correlations between C1s expression and other important clinicopathological parameters in urothelial carcinomas.

  Parameter                                 Category        Upper Urinary Tract Urothelial Carcinoma   Urinary Bladder Urothelial Carcinoma                                       
  ----------------------------------------- --------------- ------------------------------------------ -------------------------------------- ----- ----------- ----- ----- ----- -----------
  Gender                                    Male            158                                        74                                     84    0.277       216   112   104   0.251
  Female                                    182             96                                         86                                           79          35    44          
  Age (years)                               \< 65           138                                        67                                     71    0.659       121   58    63    0.587
  ≥ 65                                      202             103                                        99                                           174         89    85          
  Tumor location                            Renal pelvis    141                                        64                                     77    0.228       \-    \-    \-    \-
  Ureter                                    150             77                                         73                                           \-          \-    \-    \-    
  Renal pelvis & ureter                     49              29                                         20                                           \-          \-    \-    \-    
  Multifocality                             Single          278                                        135                                    143   0.261       \-    \-    \-    \-
  Multifocal                                62              35                                         27                                           \-          \-    \-    \-    
  Primary tumor (T)                         Ta              89                                         64                                     25    \<0.001\*   84    70    14    \<0.001\*
  T1                                        92              67                                         25                                           88          50    38          
  T2-T4                                     159             39                                         120                                          123         27    96          
  Nodal metastasis                          Negative (N0)   312                                        163                                    149   0.006\*     266   142   124   \<0.001\*
  Positive (N1-N3)                          28              7                                          21                                           29          5     24          
  Histological grade                        Low grade       56                                         40                                     16    \<0.001\*   56    45    11    \<0.001\*
  High grade                                284             130                                        154                                          239         102   137         
  Vascular invasion                         Absent          234                                        147                                    87    \<0.001\*   246   136   110   \<0.001\*
  Present                                   106             23                                         83                                           49          11    38          
  Perineural invasion                       Absent          321                                        165                                    156   0.034\*     275   142   133   0.021\*
  Present                                   19              5                                          14                                           20          5     15          
  Mitotic rate (per 10 high power fields)   \< 10           173                                        96                                     77    0.039\*     139   82    57    0.003\*
  \>= 10                                    167             74                                         93                                           156         65    91          

\* Statistically significant.

###### 

Univariate log-rank and multivariate analyses for Disease-specific and Metastasis-free Survivals in upper urinary tract urothelial carcinoma.

  Parameter                                 Category        Case No.   Disease-specific Survival   Metastasis-free Survival                                                                         
  ----------------------------------------- --------------- ---------- --------------------------- -------------------------- -------------- ---- ----------- ---- ------------ -------------- ---- -----------
  Gender                                    Male            158        28                          0.8286                     \-             \-   \-          32   0.7904       \-             \-   \-
  Female                                    182             33                                     \-                         \-             \-   38               \-           \-             \-   
  Age (years)                               \< 65           138        26                          0.9943                     \-             \-   \-          30   0.8470       \-             \-   \-
  ≥ 65                                      202             35                                     \-                         \-             \-   40               \-           \-             \-   
  Tumor side                                Right           177        34                          0.7366                     \-             \-   \-          38   0.3074       \-             \-   \-
  Left                                      154             26                                     \-                         \-             \-   32               \-           \-             \-   
  Bilateral                                 9               1                                      \-                         \-             \-   0                \-           \-             \-   
  Tumor location                            Renal pelvis    141        24                          0.0079\*                   1              \-   0.997       31   0.0659       \-             \-   \-
  Ureter                                    150             22                                     0.859                      0.462-1.598         25               \-           \-             \-   
  Renal pelvis & ureter                     49              15                                     1.334                      0.370-4.805         14               \-           \-             \-   
  Multifocality                             Single          273        48                          0.0026\*                   1              \-   0.005\*     52   0.0127\*     1              \-   \<0.001\*
  Multifocal                                62              18                                     3.026                      1.400-6.540         18               2.517        1.453-4.360         
  Primary tumor (T)                         Ta              89         2                           \<0.0001\*                 1              \-   0.015\*     4    \<0.0001\*   1              \-   0.180
  T1                                        92              9                                      5.281                      0.834-33.444        15               2.807        0.865-9.110         
  T2-T4                                     159             50                                     7.405                      1.286-42.636        51               2.657        0.823-8.582         
  Nodal metastasis                          Negative (N0)   312        42                          \<0.0001\*                 1              \-   \<0.001\*   55   \<0.0001\*   1              \-   \<0.001\*
  Positive (N1-N3)                          28              19                                     5.707                      3.085-10.558        15               3.135        1.698-5.788         
  Histological grade                        Low grade       56         4                           0.0215\*                   1              \-   0.029\*     3    0.0027\*     1              \-   0.020\*
  High grade                                284             57                                     3.507                      1.137-10.814        67               4.259        1.251-14.496        
  Vascular invasion                         Absent          234        24                          \<0.0001\*                 1              \-   0.160       26   \<0.0001\*   1              \-   0.003\*
  Present                                   106             37                                     1.531                      0.845-2.774         44               2.459        1.347-4.487         
  Perineural invasion                       Absent          321        50                          \<0.0001\*                 1              \-   \<0.001\*   61   \<0.0001\*   1              \-   0.009\*
  Present                                   19              11                                     4.045                      1.931-8.476         9                2.712        1.289-5.708         
  Mitotic rate (per 10 high power fields)   \< 10           173        27                          0.167                      \-             \-               30   0.0823       \-             \-   
  \>= 10                                    167             34                                     \-                         \-                  40               \-           \-                  
  C1s expression                            Low             170        8                           \<0.0001\*                 1              \-   \<0.001\*   18   \<0.0001\*   1              \-   0.006\*
  High                                      170             53                                     1.755                      1.385-2.225         52               1.482        1.117-1.967         

\* Statistically significant

###### 

Univariate log-rank and multivariate analyses for Disease-specific and Metastasis-free Survivals in urinary bladder urothelial carcinoma.

  Parameter                                 Category        Case No.   Disease-specific Survival   Metastasis-free Survival                                                                         
  ----------------------------------------- --------------- ---------- --------------------------- -------------------------- -------------- ---- ----------- ---- ------------ -------------- ---- -----------
  Gender                                    Male            216        41                          0.4446                     \-             \-   \-          60   0.2720       \-             \-   \-
  Female                                    79              11                                     \-                         \-             \-   16               \-           \-             \-   
  Age (years)                               \< 65           121        17                          0.1136                     \-             \-   \-          31   0.6875       \-             \-   \-
  ≥ 65                                      174             35                                     \-                         \-             \-   45               \-           \-             \-   
  Primary tumor (T)                         Ta              84         1                           \<0.0001\*                 1              \-   0.006\*     4    \<0.0001\*   1              \-   0.019\*
  T1                                        88              9                                      2.865                      1.299-6.329         23               4.177        1.216-14.343        
  T2-T4                                     123             42                                     11.764                     1.344-100           49               5.208        1.487-18.234        
  Nodal metastasis                          Negative (N0)   266        41                          0.0002\*                   1              \-   0.859       61   \<0.0001\*   1              \-   0.099
  Positive (N1-N3)                          29              11                                     1.066                      0.524-2.169         15               1.689        0.906-3.149         
  Histological grade                        Low grade       56         2                           0.0013\*                   1              \-   0.886       5    0.0007\*     1              \-   0.685
  High grade                                239             50                                     0.892                      0.187-4.264         71               0.799        0.269-2.368         
  Vascular invasion                         Absent          246        37                          0.0024\*                   1              \-   0.119       54   0.0001\*     1              \-   0.977
  Present                                   49              15                                     0.574                      0.286-1.154         22               0.991        0.534-1.838         
  Perineural invasion                       Absent          275        44                          0.0001\*                   1              \-   0.018\*     66   0.0007\*     1              \-   0.112
  Present                                   20              8                                      2.805                      1.197-6.574         10               1.834        0.868-3.878         
  Mitotic rate (per 10 high power fields)   \< 10           139        12                          \<0.0001\*                 1              \-   0.011\*     23   \<0.0001\*   1              \-   0.022\*
  \>= 10                                    156             40                                     2.379                      1.220-4.640         53               1.828        1.092-3.059         
  C1s expression                            Low             147        3                           \<0.0001\*                 1              \-   \<0.001\*   16   \<0.0001\*   1              \-   \<0.001\*
  High                                      148             49                                     11.441                     3.478-37.628        60               2.984        1.661-5.361         

\* Statistically significant
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